These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

848 related items for PubMed ID: 29495591

  • 1. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
    Di Maggio R, Hsieh MM, Zhao X, Calvaruso G, Rigano P, Renda D, Tisdale JF, Maggio A.
    Int J Mol Sci; 2018 Feb 28; 19(3):. PubMed ID: 29495591
    [Abstract] [Full Text] [Related]

  • 2. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.
    Medicine (Baltimore); 1996 Nov 28; 75(6):300-26. PubMed ID: 8982148
    [Abstract] [Full Text] [Related]

  • 3. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
    Rigano P, Pecoraro A, Calvaruso G, Steinberg MH, Iannello S, Maggio A.
    Am J Hematol; 2013 Nov 28; 88(11):E261-4. PubMed ID: 23828131
    [Abstract] [Full Text] [Related]

  • 4. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
    el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.
    Acta Haematol; 1995 Nov 28; 94(3):128-34. PubMed ID: 7502628
    [Abstract] [Full Text] [Related]

  • 5. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.
    Koren A, Segal-Kupershmit D, Zalman L, Levin C, Abu Hana M, Palmor H, Luder A, Attias D.
    Pediatr Hematol Oncol; 1999 Nov 28; 16(3):221-32. PubMed ID: 10326220
    [Abstract] [Full Text] [Related]

  • 6. Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.
    Rigano P, De Franceschi L, Sainati L, Piga A, Piel FB, Cappellini MD, Fidone C, Masera N, Palazzi G, Gianesin B, Forni GL, Italian Multicenter Study of Hydroxyurea in Sickle Cell Anemia Investigators.
    Blood Cells Mol Dis; 2018 Mar 28; 69():82-89. PubMed ID: 29107441
    [Abstract] [Full Text] [Related]

  • 7. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ.
    J Pediatr; 1996 Jun 28; 128(6):820-8. PubMed ID: 8648542
    [Abstract] [Full Text] [Related]

  • 8. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
    Pecoraro A, Rigano P, Troia A, Calzolari R, Scazzone C, Maggio A, Steinberg MH, Di Marzo R.
    Eur J Haematol; 2014 Jan 28; 92(1):66-72. PubMed ID: 24112139
    [Abstract] [Full Text] [Related]

  • 9. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.
    Blood Cells Mol Dis; 2000 Oct 28; 26(5):453-66. PubMed ID: 11112383
    [Abstract] [Full Text] [Related]

  • 10. Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels.
    Adekile A, Menzel S, Gupta R, Al-Sharida S, Farag A, Haider M, Akbulut N, Mustafa N, Thein SL.
    Am J Hematol; 2015 Jul 28; 90(7):E138-9. PubMed ID: 25851995
    [No Abstract] [Full Text] [Related]

  • 11. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).
    Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E.
    Blood; 2010 Mar 25; 115(12):2354-63. PubMed ID: 19903897
    [Abstract] [Full Text] [Related]

  • 12. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
    Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.
    Blood; 2004 Mar 15; 103(6):2039-45. PubMed ID: 14630791
    [Abstract] [Full Text] [Related]

  • 13. Minimal doses of hydroxyurea for sickle cell disease.
    Lima CS, Arruda VR, Costa FF, Saad ST.
    Braz J Med Biol Res; 1997 Aug 15; 30(8):933-40. PubMed ID: 9361721
    [Abstract] [Full Text] [Related]

  • 14. The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study.
    Koc A, Gumruk F, Gurgey A.
    Pediatr Hematol Oncol; 2003 Sep 15; 20(6):429-34. PubMed ID: 14631615
    [Abstract] [Full Text] [Related]

  • 15. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
    Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M.
    JAMA; 2003 Apr 02; 289(13):1645-51. PubMed ID: 12672732
    [Abstract] [Full Text] [Related]

  • 16. Neonatal Screening and the Clinical Outcome in Children with Sickle Cell Disease in Central India.
    Upadhye DS, Jain DL, Trivedi YL, Nadkarni AH, Ghosh K, Colah RB.
    PLoS One; 2016 Apr 02; 11(1):e0147081. PubMed ID: 26785407
    [Abstract] [Full Text] [Related]

  • 17. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients.
    Borg J, Phylactides M, Bartsakoulia M, Tafrali C, Lederer C, Felice AE, Papachatzopoulou A, Kourakli A, Stavrou EF, Christou S, Hou J, Karkabouna S, Lappa-Manakou C, Ozgur Z, van Ijcken W, von Lindern M, Grosveld FG, Georgitsi M, Kleanthous M, Philipsen S, Patrinos GP.
    Pharmacogenomics; 2012 Oct 02; 13(13):1487-500. PubMed ID: 23057549
    [Abstract] [Full Text] [Related]

  • 18. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K, Jain D, Gattani S, Jijina F, Nadkarni A, Sawant P, Nair S, Mohanty D, Ghosh K, Colah R.
    Blood Cells Mol Dis; 2009 Oct 02; 42(1):25-31. PubMed ID: 18954999
    [Abstract] [Full Text] [Related]

  • 19. Clinical and laboratory effects of long-term administration of hydroxyurea to patients with sickle-cell/beta-thalassaemia.
    Voskaridou E, Kalotychou V, Loukopoulos D.
    Br J Haematol; 1995 Mar 02; 89(3):479-84. PubMed ID: 7537527
    [Abstract] [Full Text] [Related]

  • 20. Effects of hydroxyurea treatment for patients with hemoglobin SC disease.
    Luchtman-Jones L, Pressel S, Hilliard L, Brown RC, Smith MG, Thompson AA, Lee MT, Rothman J, Rogers ZR, Owen W, Imran H, Thornburg C, Kwiatkowski JL, Aygun B, Nelson S, Roberts C, Gauger C, Piccone C, Kalfa T, Alvarez O, Hassell K, Davis BR, Ware RE.
    Am J Hematol; 2016 Feb 02; 91(2):238-42. PubMed ID: 26615793
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.